Prevalence of drug resistance and newly recognised treatment-related substitutions in the HIV-1 reverse transcriptase and protease genes from HIV-positive patients naïve for anti-retrovirals

Clinical Microbiology and Infection

Volumn 10, Issue 9, 2004, Pages 826-830

  Torti, Carlo ^a   Bono, L ^a   Gargiulo, F ^a   Uccelli, M C ^a   Quiros Roldan, E ^a   Patroni, A ^a   Paraninfo, G ^a   Tirelli, V ^a   Manca, N ^a   De Francesco, M A ^a   Perandin, F ^a   Carosi, G ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

AIDS; Anti retroviral therapy; HIV; Resistance mutations

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; EFAVIRENZ; NELFINAVIR; NEVIRAPINE; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; SEXUAL BEHAVIOR; STATISTICAL ANALYSIS; TREATMENT OUTCOME; VIRUS STRAIN;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 4644345175     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2004.00938.x     Document Type: Article

References (17)

1. Fatkenheuer G, Theisen A, Rockstroh J et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV infected patients. AIDS 1997; 11: F113-F116.
2. Little SJ, Holte S, Routy JP et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385-394.
3. Little SJ. Transmission and prevalence of HIV resistance among treatment-naïve subjects. Antivir Ther 2000; 5: 33-40.
4. Weber J, Rangel HR, Chakraborty B et al. Role of baseline pol genotype in HIV-1 fitness evolution. J AIDS 2003; 33: 448-460.
5. Perno CF, Cozzi-Lepri A, Balotta C et al. Secondary mutations in the protease region of human immunodeficiency virus and virological failure in drug naïve patients treated with protease inhibitor-based therapy. J Infect Dis 2001; 184: 983-991.
6. Masquelier B, Droz C, Dary M et al. R57K polymorphism in the human immunodeficiency virus type 1 protease as predictor of early virological failure in a cohort of anti-retroviral-naïve patients treated mostly with a nelfinavir-containing regimen. Antimicrob Agents Chemother 2003; 47: 3623-3626.
7. Gonzales MJ, Wu TD, Taylor J et al. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 2003; 17: 791-799.
8. Wu TD, Schiffer CA, Gonzales MJ et al. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol 2003; 77: 4836-4847.
9. D'Aquila RT, Shapiro JM, Brun-Vézinet F et al. Drug resistance mutations in HIV-1. Top HIV Med 2003; 11: 92-96.
10. Shulman NS, Zolopa AR, Passaro DJ et al. Efavirenz- and adenofovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response. J AIDS 2000; 23: 221-226.
11. Kozal MJ, Shah N, Shen N et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 1996; 2: 753-759.
12. Yerly S, Vora S, Rizzardi P et al. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 2001; 15: 2287-2292.
13. Wensing AMJ, van der Vijver DAMC, Asjo B et al. Prevalence of transmitted drug resistance in Europe is largely influenced by the presence of non-B sequences: analysis of 1400 patients from 16 countries: the CATCH-study. Antiviral Ther 2003; 8: S131.
14. Riva C, Violin M, Cozzi-Lepri A et al. Transmitted virus with substitutions at position 215 and risk of virological failure in antiretroviral naïve patients starting highly active antiretroviral therapy. Antiviral Ther 2002; 7: S103.
15. Van Der Vijver DAMC, Schuurman R, Nielsen C et al. A systematic approach that identifies 11 new mutations as indicators of transmission of resistance. Antiviral Ther 2003; 8: S146.
16. De Mendoza C, Rodriguez C, Corral A, Gallego O, Del Romero J, Soriano V. Evidence for a different transmission efficiency of viruses with distinct drug resistant genotypes. Antiviral Ther 2003; 8: S144.
17. Turner T, Brenner BG, Routy JP, Moisi D, Wainberg MA. Decreased rates of transmission of drug resistant HIV-1 strains containing the M184V mutation in reverse transcriptase. Antiviral Ther 2003; 8: S143.